Onderzoeker
Guy FROYEN
- Trefwoorden:Biomedische wetenschappen
- Disciplines:Analyse van next-generation sequence data, Genetica, Kankerdiagnose, Moleculaire diagnostiek
Affiliaties
- Immunologie & Infectie (Departement)
Lid
Vanaf1 jan 2020 → Heden - Immunologie & Infectie (Onderzoeksgroep)
Lid
Vanaf1 jan 2020 → Heden - Limburg Clinical Research Center (Onderzoekscentrum)
Lid
Vanaf1 jan 2020 → Heden - Geneeskunde en Levenswetenschappen (Faculteit)
Lid
Vanaf1 okt 2017 → Heden - Fysiologie - biochemie - immunologie (Departement)
Lid
Vanaf1 okt 2017 → 31 dec 2019 - Immunologie - Biochemie (Onderzoeksgroep)
Lid
Vanaf1 okt 2017 → 31 dec 2019
Projecten
1 - 1 of 1
- Het mutationele profiel in de progressie van monoklonale gammopathie van onbekende betekenis naar multipel myeloom.Vanaf1 okt 2018 → 30 sep 2021Financiering: BOF - Nieuwe Onderzoeksinitiatieven
Publicaties
1 - 10 van 12
- Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications(2023)
Auteurs: Olivia Vandekerckhove, Kristof CUPPENS, Karin Pat, Bert Du Pont, Guy FROYEN, Brigitte MAES
- Reliability of panel-based mutational signatures for immune-checkpoint-inhibition efficacy prediction in non-small cell lung cancer(2023)
Auteurs: H. C. Donker, Kristof CUPPENS, Guy FROYEN, H. J. M. Groen, T. J. N. Hiltermann, Brigitte MAES, E. Schuuring, P. -J. Volders, G. A. Lunter, B. van Es
- HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors(2022)
Auteurs: Kristof CUPPENS, Paul Baas, Ellen GEERDENS, Bert Cruys, Guy FROYEN, Lynn Decoster, Michiel THOMEER, Brigitte MAES
Pagina's: 1 - 10 - Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors(2022)
Auteurs: Guy FROYEN, Ellen GEERDENS, Severine Berden, Bert Cruys, Brigitte Maes
- The Dynamics of Nucleotide Variants in the Progression from Low–Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach(2022)
Auteurs: Bénedith OBEN, Charlotte COSEMANS, Ellen GEERDENS, Loes LINSEN, Kimberly VANHEES, Brigitte MAES, Koen Theunissen, Bert Cruys, Marta Lionetti, Ingrid ARIJS, et al.
- Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities(2021)
Auteurs: Bénedith OBEN, Guy FROYEN, Kylee H. Maclachlan, Daniel Leongamornlert, Federico Abascal, Binbin Zheng-Lin, Venkata Yellapantula, Andriy Derkach, Ellen GEERDENS, Benjamin T. Diamond, et al.
- The dynamics of nucleotide variants in the progression from myeloma precursor conditions to multiple myeloma using targeted sequencing of serial bone marrow samples(2021)
Auteurs: Bénedith OBEN, Charlotte COSEMANS, Ellen GEERDENS, Loes LINSEN, Kimberly VANHEES, Brigitte MAES, Koen Theunissen, Bert Cruys, Marta Lionetti, Ingrid ARIJS, et al.
Pagina's: S70 - S70 - 1037P Tumour mutational burden and HLA diversity by TruSight oncology 500 (TSO500) next generation sequencing panel and clinical outcome in non-small cell lung cancer(2020)
Auteurs: Kristof CUPPENS, Guy FROYEN, B. Cruys, Ellen GEERDENS, S. Zhang, B. Zhang, L. Decoster, Michiel THOMEER, Brigitte MAES
Pagina's: S713 - S714 - Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel(2019)
Auteurs: Guy FROYEN, Marie Le Mercier, Els Lierman, Karl Vandepoele, Friedel Nollet, Elke Boone, Joni Van der Meulen, Koen Jacobs, Suzan Lambin, Sara Vander Borght, et al.
- Archival May-Grunwald-Giemsa-Stained Bone Marrow Smears Are an Eligible Source for Molecular DNA Research(2018)
Auteurs: Bénedith OBEN, Charlotte COSEMANS, Ingrid ARIJS, Loes LINSEN, Annick Daniels, Jeroen DECLERCQ, Brigitte MAES, Kimberly VANHEES, Guy FROYEN, Jean-Luc RUMMENS
Pagina's: 274 - 281